Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy

Cancer immunotherapy has a long developmental history, beginning with William Coley’s first bacterial mixture (‘Coley’s toxin’) in 1891, which led to the development of nonspecific immunotherapy. After the research team of Thierry Boon succeeded in isolating the first melanoma antigen gene (MAGE-1)...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hiromichi Nakajima, Tetsuya Nakatsura
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2021-01-01
coleção:	Immunological Medicine
Assuntos:	cancer immunotherapy tumor antigen specific immunotherapy immune checkpoint inhibitor personalized immunotherapy
Acesso em linha:	http://dx.doi.org/10.1080/25785826.2020.1785654
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!